JP2020522261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522261A5 JP2020522261A5 JP2019566609A JP2019566609A JP2020522261A5 JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5 JP 2019566609 A JP2019566609 A JP 2019566609A JP 2019566609 A JP2019566609 A JP 2019566609A JP 2020522261 A5 JP2020522261 A5 JP 2020522261A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 20
- 101710043865 Nectin-4 Proteins 0.000 claims 17
- 102100035486 Nectin-4 Human genes 0.000 claims 17
- 238000000034 method Methods 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 101001023705 Homo sapiens Nectin-4 Proteins 0.000 claims 3
- 102000043460 human nectin4 Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000002055 immunohistochemical effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515454P | 2017-06-05 | 2017-06-05 | |
| US62/515,454 | 2017-06-05 | ||
| PCT/US2018/035840 WO2018226578A1 (en) | 2017-06-05 | 2018-06-04 | Nectin-4-binding proteins and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522261A JP2020522261A (ja) | 2020-07-30 |
| JP2020522261A5 true JP2020522261A5 (OSRAM) | 2021-07-26 |
| JP7168590B2 JP7168590B2 (ja) | 2022-11-09 |
Family
ID=64566092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566609A Active JP7168590B2 (ja) | 2017-06-05 | 2018-06-04 | ネクチン４結合性タンパク質及びその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11292837B2 (OSRAM) |
| EP (1) | EP3635013A4 (OSRAM) |
| JP (1) | JP7168590B2 (OSRAM) |
| KR (1) | KR102723905B1 (OSRAM) |
| CN (2) | CN111675761B (OSRAM) |
| BR (1) | BR112019025513A2 (OSRAM) |
| CA (1) | CA3065514A1 (OSRAM) |
| MX (1) | MX2019014318A (OSRAM) |
| TW (1) | TWI870338B (OSRAM) |
| WO (1) | WO2018226578A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| EP3890778A4 (en) | 2018-12-03 | 2022-08-03 | Agensys, Inc. | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME |
| CN110172455B (zh) * | 2019-05-31 | 2020-03-17 | 江南大学 | 一种脂肪酶突变体及其在去污方面的应用 |
| AU2020364959A1 (en) | 2019-10-07 | 2022-04-07 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for Nectin-4 and uses thereof |
| KR102280672B1 (ko) * | 2019-12-20 | 2021-07-23 | 주식회사 베르티스 | 암의 진단용 조성물 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| US20230235054A1 (en) * | 2020-06-18 | 2023-07-27 | Bioatla, Inc. | Conditionally active anti-nectin-4 antibodies |
| EP4168039A4 (en) * | 2020-06-19 | 2024-12-04 | Agensys, Inc. | MARKER FOR USE IN METHODS OF TREATING CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) |
| US20230331867A1 (en) * | 2020-09-04 | 2023-10-19 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| BR112022026611A2 (pt) * | 2020-09-16 | 2023-04-11 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Anticorpo ou fragmento de ligação ao antígeno do mesmo, conjugado de anticorpo, composição, receptor de antígeno quimérico, célula efetora imune, molécula de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo multiespecífico, proteína de fusão, composição farmacêutica, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para detectar a presença ou determinar o nível de expressão de nectina-4 em uma amostra |
| IL302818A (en) * | 2020-11-25 | 2023-07-01 | Innate Pharma | Treatment of cancer |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| BR112023022098A2 (pt) * | 2021-04-26 | 2023-12-19 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-nectina-4 e conjugado anticorpo-fármaco anti-nectina-4 e uso medicinal dos mesmos |
| US12258402B2 (en) | 2022-01-12 | 2025-03-25 | Navi Bio-Therapeutics, Inc. | Antibody specific to nectin cell adhesion molecule 4 and uses thereof |
| EP4496593A1 (en) | 2022-03-23 | 2025-01-29 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| WO2023198011A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Single domain anti-nectin-4 antibodies |
| WO2023198007A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Anti-nectin-4 antibodies and bispecific antibodies |
| WO2023198008A1 (en) * | 2022-04-11 | 2023-10-19 | Bj Bioscience Inc. | Compositions and methods for treating cancer |
| EP4310101A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibodies and antibody-drug conjugates |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| KR102584898B1 (ko) * | 2022-10-24 | 2023-10-04 | 연세대학교 산학협력단 | 자궁내막암 진단 방법 및 이를 이용한 키트 |
| WO2024251260A1 (zh) * | 2023-06-08 | 2024-12-12 | 江苏迈威康新药研发有限公司 | 结合Nectin-4的抗体及其用途 |
| JP7689606B2 (ja) * | 2023-06-20 | 2025-06-06 | イーライ リリー アンド カンパニー | ネクチン－４抗体及び抗体－薬物コンジュゲート |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1747236A1 (en) | 2004-05-12 | 2007-01-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nectin 4(n4) as a marker for cancer prognosis |
| GB0807018D0 (en) | 2008-04-17 | 2008-05-21 | Fusion Antibodies Ltd | Antibodies and treatment |
| JP2012511305A (ja) | 2008-12-12 | 2012-05-24 | オンコセラピー・サイエンス株式会社 | 癌の治療および診断の標的遺伝子としてのネクチン−４ |
| EA201790850A1 (ru) | 2010-09-29 | 2017-11-30 | Эдженсис, Инк. | Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12 |
| WO2016203053A2 (en) | 2015-06-18 | 2016-12-22 | Thomas Mole Herd | Methods of characterising cancer |
| US10675357B2 (en) * | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
-
2018
- 2018-06-04 BR BR112019025513-3A patent/BR112019025513A2/pt unknown
- 2018-06-04 CA CA3065514A patent/CA3065514A1/en active Pending
- 2018-06-04 MX MX2019014318A patent/MX2019014318A/es unknown
- 2018-06-04 JP JP2019566609A patent/JP7168590B2/ja active Active
- 2018-06-04 US US16/619,439 patent/US11292837B2/en active Active
- 2018-06-04 KR KR1020197038453A patent/KR102723905B1/ko active Active
- 2018-06-04 WO PCT/US2018/035840 patent/WO2018226578A1/en not_active Ceased
- 2018-06-04 TW TW107119234A patent/TWI870338B/zh active
- 2018-06-04 CN CN202010492265.3A patent/CN111675761B/zh active Active
- 2018-06-04 EP EP18813335.9A patent/EP3635013A4/en active Pending
- 2018-06-04 CN CN201880049820.6A patent/CN111051345A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522261A5 (OSRAM) | ||
| ES2692522T3 (es) | Anticuerpo anti-cMet y su utilización para la detección y el diagnóstico del cáncer | |
| RU2425841C2 (ru) | Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38 | |
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| JP2021500916A5 (OSRAM) | ||
| IL261666B2 (en) | Binding proteins and methods of use thereof | |
| JP2013506428A5 (OSRAM) | ||
| JP2017535257A5 (OSRAM) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| JP2014512809A5 (OSRAM) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| WO2014089209A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| JP2017507131A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| JP2016516400A5 (OSRAM) | ||
| JP2017532005A5 (OSRAM) | ||
| JP2014518630A5 (OSRAM) | ||
| JP2024029261A5 (OSRAM) | ||
| JP2018525320A5 (OSRAM) | ||
| EP3954999B1 (en) | Compositions and methods for detecting and treating ovarian cancer | |
| JP2018508467A (ja) | 抗ｉｌ−３４抗体 | |
| CA3058263C (en) | Compositions and methods for detecting prostate cancer | |
| CN109069606A (zh) | 干扰素β抗体及其用途 |